Healthcare / Drug Manufacturers - GeneralUpdated 2026-05-10 22:07 UTC

NSE/SMSPHARMA stock hub

NSE/SMSPHARMA has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/SMSPHARMAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

39B

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/SMSPHARMA

In the news

Latest news · NSE/SMSPHARMA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 24.9P50 32.4P75 45.7

Trailing P/E43.3

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC10.4

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/SMSPHARMA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

195

Groups with data

Currency

INR

Showing 195 of 195 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	1,470
Employees Change	273%
Employees Change Percent	22.81
Enterprise value	INR 41.2B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - General
Isin	INE812G01025
Last refreshed	2026-05-10
Market cap	INR 39B
Price	INR 413
Price currency	INR
Rev Per Employee	6,102,851.02x
Sector	Healthcare
Sic	2833
Symbol	nse/SMSPHARMA
Website	https://smspharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.3%
EV Earnings	46.03x
EV/EBIT	30.22x
EV/EBITDA	23.85x
EV/Sales	4.6x
P/B ratio	5.35x
P/E ratio	43.31x
P/S ratio	4.35x
PE Ratio10 Y	43.17x
PE Ratio3 Y	34.33x
PE Ratio5 Y	75.24x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	14.94%
EBITDA Margin	18.95%
Gross margin	32.47%
Gross Profit	INR 2.9B
Gross Profit Growth	17.89%
Gross Profit Growth Q	11.59%
Gross Profit Growth3 Y	43.27%
Gross Profit Growth5 Y	14.14%
Net Income	INR 895.9M
Net Income Growth	35.54%
Net Income Growth Q	28.67%
Net Income Growth Quarters	11%
Net Income Growth Years	2%
Net Income Growth5 Y	14.37%
Pretax Margin	13.44%
Profit Margin	9.99%
Profit Per Employee	INR 609,461
Profitable Years	2
Roa5y	5.64
Roe5y	10.17
ROIC	10.44
Roic5y	9.1

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	16.86%
Cagr15y	22.89%
Cagr1y	72.72%
Cagr3y	69.87%
Cagr5y	21.88%
Div CAGR10	7.18%
Div CAGR3	10.06%
Div CAGR5	5.92%
EPS Growth	22.95
EPS Growth Q	20.47
EPS Growth Quarters	11
EPS Growth Years	2
EPS Growth5 Y	12.18
Revenue Growth	14.96x
Revenue Growth Q	21.4x
Revenue Growth Quarters	13x
Revenue Growth Years	3x
Revenue Growth3 Y	27.43x
Revenue Growth5 Y	12.81x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	INR 996.8M
Debt	INR 3.2B
Debt EBITDA	INR 1.9
Debt Equity	INR 0.44
Equity	INR 7.3B
Interest Coverage	6.16
Net Cash	INR -2.2B
Net Cash By Market Cap	INR -5.76
Net Debt EBITDA	INR 1.32
Net Debt Equity	INR 0.31
Tangible Book Value	INR 7.3B
Tangible Book Value Per Share	INR 81.54
WACC	6.33

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-10.24%
Dividend Growth	0%
Dividend Growth Years	0%
Dividend per share	INR 0.4
Dividend Years	13
Dividend Yield	0.1%
Ex Div Date	2025-09-22
Last Dividend	INR 0.4
Payout Frequency	Annual

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	374.87%
1Y total return	72.65%
200-day SMA	313.6
3Y total return	390.3%
50-day SMA	396.2
50-day SMA vs 200-day SMA	50over200
5Y total return	168.94%
All Time High	447.8
All Time High Change	-7.77%
All Time High Date	2026-04-15
All Time Low	7.4
All Time Low Change	5,481.08%
All Time Low Date	2009-01-15
ATR	18.67
Beta	0.4
Beta1y	1.09
Beta2y	1.05
Ch YTD	33.05
High	427.4
High52	447.8
High52 Date	2026-04-15
High52ch	-7.77%
Low	411
Low52	207.7
Low52 Date	2025-06-19
Low52ch	98.84%
Ma50ch	4.24%
Price vs 200-day SMA	31.7%
RSI	54.89
RSI Monthly	74.34
RSI Weekly	66.74
Sharpe ratio	1.34x
Sortino ratio	2.5
Total Return	-10.15%
Tr YTD	33.05
Tr15y	2,101.21%
Tr1m	5.88%
Tr1w	1.69%
Tr3m	29.87%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 1.3B
Operating Income Growth	35.23
Operating Income Growth Q	37.19
Operating Income Growth5 Y	12.33
Operating margin	14.94

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	23,315,294%
Shares Insiders	64.29%
Shares Institutions	3.21%
Shares Out	93,652,030
Shares Qo Q	1.68%
Shares Yo Y	10.24%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	303,222.65x
Bv Per Share	81.83
Ch10y	359.9
Ch15y	1,973.8
Ch1m	5.88
Ch1w	1.69
Ch1y	72.41
Ch3m	29.87
Ch3y	387.9
Ch5y	166.2
Ch6m	42.78
Change	-2.02%
Change From Open	-0.4
Close	421.5
Days Gap	-1.63
Depreciation Amortization	360,092,000
Dollar Volume	106,668,814
Earnings Date	2026-05-26
EBIT	INR 1.3B
EBITDA	INR 1.7B
EPS	INR 9.61
F Score	2
Fiscal Year End	March
Founded	1,987
Graham Number	133.03669
Graham Upside	-67.79
Income Tax	INR 309.8M
Is Primary Listing	1
Last Earnings Date	2026-02-07
Last Report Date	2025-12-31
Last Split Date	2015-12-17
Last Split Type	Forward
Lynch Fair Value	INR 138
Lynch Upside	-66.55
Ma150	335.7
Ma150ch	23.04%
Ma20	413.2
Ma20ch	-0.06%
Next Earnings Date	2026-05-26
Open	414.7
Payment Date	2025-10-29
Position In Range	12.2
Price Date	2026-05-08
Price EBITDA	INR 22.93
Ptbv Ratio	5.37
Relative Volume	0.85x
Revenue	8,971,191,000x
Tax By Revenue	3.45x
Tax Rate	25.69%
Tr6m	42.78%
Volume	258,278

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/SMSPHARMA dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.1%

$0.40 annual per share

Payout ratio

n/a

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+5.9%

0 consecutive years of growth

Total shareholder yield

-10.1%

Next ex-dividend date: 2025-09-22

Performance

NSE/SMSPHARMA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/SMSPHARMA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+3.2%

Share of float held by funds and institutions

Insider ownership

+64.3%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+10.2%

Negative means the company is buying back shares.

Technical

NSE/SMSPHARMA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

54.9

Neutral momentum band

Price vs 200-day MA

+31.7%

50/200-day relationship not available

Beta (5Y)

0.40

Less volatile than the market

Sharpe ratio

1.34

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/SMSPHARMA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/SMSPHARMA stock rating?

nse/SMSPHARMA is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/SMSPHARMA analysis?

The full report lives at /stocks/nse/SMSPHARMA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/SMSPHARMA?

The latest report frames nse/SMSPHARMA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/SMSPHARMA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.